Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bartsch

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Clinical & Experimental Metastasis|November 14, 2018
Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care centerL M Füreder, G Widhalm, B Gatterbauer, et al.
Breast Cancer Research and Treatment|January 22, 2010
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, C Wiltschke, J Jasinska, et al.
Plos One|August 14, 2013
Fatty acid composition at the base of aquatic food webs is influenced by habitat type and watershed land useJames H Larson, William B Richardson, Brent C Knights, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experienceG G Steger, R Bartsch, C Wenzel, et al.
British Journal of Cancer|April 14, 2015
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trialF Fitzal, M Filipits, M Rudas, et al.
Epilepsy Research|April 1, 1996
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizuresA Rostock, C Tober, C Rundfeldt, et al.
The British Journal of Surgery|February 20, 2021
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trialF Fitzal, M Filipits, C Fesl, et al.
British Journal of Cancer|June 1, 2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case seriesF Zagouri, T N Sergentanis, V Koutoulidis, et al.
British Journal of Cancer|July 9, 2014
The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancerR Exner, Z Bago-Horvath, R Bartsch, et al.
British Journal of Cancer|February 21, 2013
High MET expression is an adverse prognostic factor in patients with triple-negative breast cancerF Zagouri, Z Bago-Horvath, F Rössler, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Clinical & Experimental Metastasis|November 14, 2018
Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care centerL M Füreder, G Widhalm, B Gatterbauer, et al.
Breast Cancer Research and Treatment|January 22, 2010
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, C Wiltschke, J Jasinska, et al.
Plos One|August 14, 2013
Fatty acid composition at the base of aquatic food webs is influenced by habitat type and watershed land useJames H Larson, William B Richardson, Brent C Knights, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2005
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experienceG G Steger, R Bartsch, C Wenzel, et al.
British Journal of Cancer|April 14, 2015
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trialF Fitzal, M Filipits, M Rudas, et al.
Epilepsy Research|April 1, 1996
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizuresA Rostock, C Tober, C Rundfeldt, et al.
The British Journal of Surgery|February 20, 2021
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trialF Fitzal, M Filipits, C Fesl, et al.
British Journal of Cancer|June 1, 2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case seriesF Zagouri, T N Sergentanis, V Koutoulidis, et al.
British Journal of Cancer|July 9, 2014
The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancerR Exner, Z Bago-Horvath, R Bartsch, et al.
British Journal of Cancer|February 21, 2013
High MET expression is an adverse prognostic factor in patients with triple-negative breast cancerF Zagouri, Z Bago-Horvath, F Rössler, et al.
Pageof 12